Cipla Limited has introduced Yurpeak (tirzepatide) in India, a once?weekly injectable therapy aimed at managing obesity and type?2 diabetes mellitus. After approval by DCGI, the company will market and sell Yurpeak the second brand of tirzepatide...
Roche today released new three-year data showing that Columvi in combination with GemOx continues to deliver major survival gains for people with relapsed or refractory DLBCL who are not candidates for transplant.After a median 35.1-month...
Pharmaceutical giant Eli Lilly is committing over $6 billion to build an advanced manufacturing plant in Huntsville, Alabama — a major push to bolster U.S.-based drug production. The new facility will focus on making active pharmaceutical...
In a promising leap for rare disease care, Recursion Pharmaceuticals revealed that its investigational drug REC-4881 delivered strong polyp reduction in patients with Familial Adenomatous Polyposis (FAP), a rare hereditary condition that...
Big news today from Venus Remedies, as the company confirmed receiving the final Rs 11 crore milestone from Cipla for its novel AMR-focused anti-infective. This marks the completion of all commercial milestones agreed under their 2019 deal...
Novo Nordisk has officially closed its acquisition of Akero Therapeutics, marking a major move in the race to develop next-generation treatments for metabolic liver diseases. The deal, first announced on October 9, 2025, is now fully completed...
Pfizer is drawing global attention today with new Phase 3 data showing its investigational therapy HYMPAVZI could shift treatment for people with hemophilia A or B who develop inhibitors. These patients often face some of the toughest treatment...
India’s rising weight burden is pushing healthcare forward, and Agilus Diagnostics is stepping in with a bold move. The company has rolled out its new obesity test suite, built to give clinicians deeper insight into insulin resistance, metabolic...
Immutep has sealed a wide-reaching licensing pact with Dr Reddy’s Laboratories, giving the Indian drugmaker exclusive rights to develop and commercialize Eftilagimod Alfa (efti) across most global markets, except North America, Europe, Japan, and...
Trivitron Healthcare and ResoHealth have established a joint venture called Trivitron Digital.AI (TDAI), which is a cutting-edge digital health initiative designed to address the existing adoption gaps on a large scale
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")